Form D · Biotechnology

Entrada Therapeutics, Inc.

Boston, MA · CIK 0001689375

Offering snapshot reported Apr 13, 2021 · SEC filing

Reported sold
$116M
Offering amount: $116M
Investors reported
26
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 29, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 13, 2021Initial$116,249,999No comparison26SEC filing
Dec 26, 2019Amendment$34,021,752$0vs Dec 26, 201810SEC filing
Dec 26, 2018Initial$34,021,752No comparison10SEC filing
Nov 10, 2016Initial$599,999No comparison2SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-395485

Source: Form D, filed Apr 13, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Christine Brennan Director
John F. Crowley Director
Dipal Doshi Director, Executive
Nathan Dowden Executive
Todd Foley Director
Anja Harmeier Director
Peter Kim Director
Nerissa Kreher Executive
Carole Nuechterlein Director
Kush M. Parmar Director
Dehua Pei Director
Mario Saltarelli Executive
Natarajan Sethuraman Executive
Louis Tartaglia Director
Kory Wentworth Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
6 Tide Street
Boston, MA, 02210